Milestone Pharmaceuticals Inc.(MIST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MIST Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Milestone Pharmaceuticals Inc. (MIST), a Healthcare sector company. MIST is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Milestone Pharmaceuticals Inc. reports quarterly revenue of $559.0K, net income of $-28.6M, free cash flow of $-22.7M. Top institutional holders of MIST by reported 13-F value include Pavaki Capital Management, RTW INVESTMENTS, Propel Bio Management, based on the most recent SEC filings. MIST trades on the Nasdaq exchange and files with the SEC under CIK 1408443. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MIST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Milestone Pharmaceuticals Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$559.0K
Net Income
Q2 2026
$-28.6M
Free Cash Flow
Q2 2026
$-22.7M
D/E Ratio
Q2 2026
3.25
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-51.9% YoYOperating Income
-47.6% YoYEPS (Diluted)
-11.9% YoYTotal Assets
+50.4% YoYTotal Debt
+7.2% YoYOp. Cash Flow
-70.0% YoYFree Cash Flow
-70.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-63.1M -51.9% | $-41.5M +30.4% | $-59.7M -2.2% | $-58.4M -36.3% | $-42.9M +14.2% | $-50.0M |
| Operating Income | $-62.1M -47.6% | $-42.1M +31.1% | $-61.1M -2.4% | $-59.6M -38.5% | $-43.1M +15.1% | $-50.7M |
| EPS (Diluted) | $-0.75 -11.9% | $-0.67 +51.8% | $-1.39 -0.7% | $-1.38 -35.3% | $-1.02 +40.0% | $-1.70 |
| Total Assets | $113.6M +50.4% | $75.5M +0.4% | $75.2M +1.0% | $74.5M -37.9% | $119.8M -20.1% | $150.0M |
| Total Debt | $57.2M +7.2% | $53.4M +7.2% | $49.8M | — | — | — |
| Operating Cash Flow | $-49.0M -70.0% | $-28.8M +37.9% | $-46.4M +11.5% | $-52.5M -57.9% | $-33.2M +34.5% | $-50.7M |
| Free Cash Flow | $-49.3M -70.8% | $-28.9M +37.9% | $-46.5M +11.8% | $-52.7M | — | — |
Get alerted when MIST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Milestone Pharmaceuticals Inc. including:
Top Institutional Holders of MIST
Pavaki Capital Management LLC
$12.2M9,067,848 shRTW INVESTMENTS, LP
$10.5M7,833,336 shPropel Bio Management, LLC
$10.0M7,429,590 shPoint72 Asset Management, L.P.
$7.3M5,411,138 shSimplify Asset Management Inc.
$4.5M3,349,379 shMILLENNIUM MANAGEMENT LLC
$4.2M3,142,219 shTWO SIGMA INVESTMENTS, LP
$2.7M2,040,015 shMARSHALL WACE, LLP
$2.4M1,797,695 shKalehua Capital Management LLC
$1.7M1,269,237 shLion Point Capital, LP
$1.1M820,000 sh
| Fund | Value | Shares |
|---|---|---|
| Pavaki Capital Management LLC | $12.2M | 9,067,848 |
| RTW INVESTMENTS, LP | $10.5M | 7,833,336 |
| Propel Bio Management, LLC | $10.0M | 7,429,590 |
| Point72 Asset Management, L.P. | $7.3M | 5,411,138 |
| Simplify Asset Management Inc. | $4.5M | 3,349,379 |
| MILLENNIUM MANAGEMENT LLC | $4.2M | 3,142,219 |
| TWO SIGMA INVESTMENTS, LP | $2.7M | 2,040,015 |
| MARSHALL WACE, LLP | $2.4M | 1,797,695 |
| Kalehua Capital Management LLC | $1.7M | 1,269,237 |
| Lion Point Capital, LP | $1.1M | 820,000 |
More Healthcare Companies
View all Healthcare →Put MIST on your watchlist
Track score changes the day Milestone Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MIST a good stock to buy?
13F Pro's AI-powered analysis of Milestone Pharmaceuticals Inc. (MIST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MIST are available on the MIST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MIST is classified as a small company.
Which hedge funds own MIST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MIST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Milestone Pharmaceuticals Inc.'s investment landscape.